-
EP2566511
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2566511
| EP2566511 - USE OF AN ANTI-CD71 ANTIBODY FOR PREPARING A MEDICAMENT [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 24.04.2015 Database last updated on 19.10.2024 | Most recent event Tooltip | 24.04.2015 | Application deemed to be withdrawn | published on 27.05.2015 [2015/22] | Applicant(s) | For all designated states Laboratoire Français du Fractionnement et des Biotechnologies 3 avenue des Tropiques ZA de Courtaboeuf 91940 Les Ulis / FR | [N/P] |
| Former [2013/34] | For all designated states Laboratoire Français du Fractionnement et des Biotechnologies 3 avenue des Tropiques ZA de Courtaboeuf 91940 Les Ulis / FR | ||
| Former [2013/11] | For all designated states LFB Biotechnologies 3 Avenue des Tropiques BP 305 Les Ulis 91958 Courtaboeuf / FR | Inventor(s) | 01 /
BOUMSELL, Laurence c/o Institut Cochin INSERM U1016 22 rue Méchain 75014 Paris / FR | [2013/11] | Representative(s) | Grosset-Fournier, Chantal Catherine, et al Grosset-Fournier & Demachy 54, rue Saint-Lazare 75009 Paris / FR | [N/P] |
| Former [2013/11] | Grosset-Fournier, Chantal Catherine, et al Grosset-Fournier & Demachy 54, rue Saint-Lazare 75009 Paris / FR | Application number, filing date | 11723558.0 | 03.05.2011 | WO2011FR51005 | Priority number, date | FR20100053426 | 03.05.2010 Original published format: FR 1053426 | [2013/11] | Filing language | FR | Procedural language | FR | Publication | Type: | A2 Application without search report | No.: | WO2011138557 | Date: | 10.11.2011 | Language: | FR | [2011/45] | Type: | A2 Application without search report | No.: | EP2566511 | Date: | 13.03.2013 | Language: | FR | The application published by WIPO in one of the EPO official languages on 10.11.2011 takes the place of the publication of the European patent application. | [2013/11] | Search report(s) | International search report - published on: | EP | 29.12.2011 | Classification | IPC: | A61K39/395, C07K16/28 | [2013/11] | CPC: |
C07K16/2881 (EP,US);
A61K39/39558 (US);
A61K31/69 (US);
A61P35/00 (EP);
G01N33/57492 (US);
A61K2039/505 (EP,US);
C07K2317/76 (EP,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/11] | Title | German: | VERWENDUNG EINES ANTI-CD71-ANTIKÖRPERS FÜR DIE ZUBEREITUNG EINES MEDIKAMENTS | [2013/11] | English: | USE OF AN ANTI-CD71 ANTIBODY FOR PREPARING A MEDICAMENT | [2013/11] | French: | UTILISATION D'ANTICORPS ANTI-CD71 POUR LA PREPARATION D'UN MEDICAMENT | [2013/11] | Entry into regional phase | 30.11.2012 | National basic fee paid | 30.11.2012 | Designation fee(s) paid | 30.11.2012 | Examination fee paid | Examination procedure | 30.11.2012 | Examination requested [2013/11] | 24.06.2013 | Amendment by applicant (claims and/or description) | 11.12.2014 | Application deemed to be withdrawn, date of legal effect [2015/22] | 14.01.2015 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2015/22] | Fees paid | Renewal fee | 27.05.2013 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 31.05.2014 | 04 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO2005094364 (CHIMERIC TECHNOLOGIES INC [US], et al) [Y] 1-10 * paragraphs [0005] , [0006] , [0013] - [0016] - [0 43]; claims 1-8 *; | [Y]WO2007000671 (MONOCLONAL ANTIBODIES THERAPEU [FR], et al) [Y] 1-10 * claims 1-3,20-22 *; | [Y] - TAETLE R ET AL, "Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH FEB 1996 LNKD- PUBMED:9816167, (199602), vol. 2, no. 2, ISSN 1078-0432, pages 253 - 259, XP002600166 [Y] 1-10 * page 257, column 2, paragraph 2 * | by applicant | - FONSECA ET AL., BLOOD, (2003), vol. 101, pages 4569 - 4575 | - AVET-LOISEAU ET AL., BLOOD, (2007), vol. 109, pages 3489 - 3495 | - BOYUM ET AL., SCAND. J. CLIN. LAB. INVEST. SUPPL., (1976), vol. 5, pages 9 - 15 |